BMC128
Renal cell carcinoma and non‑small cell lung cancer
Phase 1Active
Key Facts
About Biomica
Biomica develops microbiome‑engineered cancer therapeutics, with its lead candidate BMC128 having cleared Phase 1.
View full company profileRenal cell carcinoma and non‑small cell lung cancer
Biomica develops microbiome‑engineered cancer therapeutics, with its lead candidate BMC128 having cleared Phase 1.
View full company profile